药理学

您所在的位置:首页 >> 师资力量 >> 张小雷

张小雷 [副教授,博士生导师]

张小雷

联系方式

办公电话:020-39943021

电子邮箱:zhangxlei5@mail.sysu.edu.cn

办公地址:广州市大学城外环东路132号 中山大学药学院,邮编:510006

简单介绍

张小雷,博士,中山大学药学院副教授/博士生导师。主要从事抗癌靶向药物开发及相关药理机制研究,以及代谢类疾病的转化医学研究。

张小雷博士作为主要研究人员领导和参与了多个美国国立卫生部(NIH)的重大研究项目,并拥有多项原创性成果,其发现被来自世界上20多个国家的100多所大学和研究机构引用和正面评价。已经有不少科学家以张小雷博士所开发的小分子药物作为研究工具推进其工作。部分小分子先导化合物已经实现了专利转让和商品化,一部分已经在EMD Millpore, VWR, Thomas Scientific, NAMIKI SHOJI等国际生物工程公司出售,供科学家们使用来推动他们在相关领域的科学创新。张小雷博士在PNAS, Cancer Research, Oncogene, Biomaterials等国际一流杂志上发表多篇论文, 一些论文被ISI Web Knowledge评为“Highly Cited Paper”,其引用率在相关领域处于“ TOP 1%”。他还以开发出的小分子药物作为研究工具来探究肿瘤的耐药性机制,并与纳米学科的团队合作将小分子药物偶联到纳米颗粒上来提升其胞内运输效率和靶向性。


研究方向

1) 高通量、高内涵新药筛选体系构建,靶向药物开发和药理机制研究 (Drug Discovery basing on High Throughput and High Contenct Screening)

2) 靶向药物与免疫治疗药物的协同抗肿瘤作用 (Targeted Agents and Immunology in Cancer Therapeutics)

3)以小分子药物为研究工具探索相关信号通路在肿瘤代谢和免疫方面的作用机制,从而为癌症的治疗提供新的方法或靶点(Cancer Metabolism and Novel Target Identification)。


教育经历

1999.09-2003.07 吉林大学生命科学学院,本科 (BS)

2003.09-2006.07 吉林大学生命科学学院,硕士 (MS)

2007.08-2011.08 中佛罗里达大学医学院,博士 (PhD)


工作经历

2017.08-至今 中山大学药学院(School of Pharmaceutical Sciences, Sun Yat-Sen University )副教授、博士生导师

2014.02-2017.08 美国佛罗里达医院转化医学研究所  (Translational Research Institute by Florida Hospital and SBP Medical Discovery Institute)  研究科学家

2011.10-2014.02 美国Moffitt癌症中心 Moffitt Cancer Center 博士后、I级研究科学家

2007.08-2011.08 中佛罗里达大学(University of Central Florida), 研究助理


社会/学术任职

被邀请担任多个国际科学杂志的审稿人, 诸如 Carcinogenesis, Biodrugs, Journal of Drug Targeting, Onco Targets and Therapy, Drug Delivery and Translational Research, International Journal of Nanomedicine, Current Oncology, Genetic Testing and Molecular Biomarkers, Journal of Breast Cancer

学术会员:AACR, ADA and ACSM


科研项目

中山大学百人计划二期启动项目


论著专利

代表性论文:

1. Xiaolei Zhang, Peibin Yue , Brent D.G. Page , Tianshu Li , Wei Zhao , Andrew T. Namanja , David Paladino , Jihe Zhao , Yuan Chen , Patrick T. Gunning , James Turkson . Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. USA (PNAS) 2012, 109 (24): 9623-9628

 

2. Zhang X, Blaskovich MA, Forinash KD, Sebti SM.  Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. British Journal of Cancer. 2014,111(5):894-902

 

3.Xiaolei Zhang, Ying Sun, Roberta Pireddu, Hua Yang, Murali K. Urlam , Harshani Lawrence , Wayne C. Guida , Nicholas J. Lawrence, Said M Sebti. A novel STAT3-STAT3 dimerization disruptor, S3I-1757, selectively suppresses STAT3 activity and malignant transformation. Cancer Research 2013, 73(6):1922-1933

 

4. Teng P*, Zhang X*, Wu H, Qiao Q, Sebti SM, Cai J. Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library. Chem Commun (Camb). 2014 Aug 14;50(63):8739-42. (*Co-first Author)

 

5. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010, 79(10):1398-409.

 

6. Peibin Yue, Xiaolei Zhang, David Paladion, James Turkson. Hyperactive EGF receptor and Stat3 signaling promote enhanced colony-forming ability motility and migration of Cisplatin-resistant ovarian cancer cells. Oncogene 2012, 31(18):2309-22

 

7. Astha Malhotra, Xiaolei Zhang, James Turkson, Swadeshmukul Santra. Buffer-Stable Chitosan–Polyglutamic Acid Hybrid Nanoparticles for Biomedical Applications. Macromolecular Bioscience 2013 May;13(5):603-13

 

8. Awet Tecleab, Xiaolei Zhang and Said M. Sebti Ral GTPase down regulation stabilizes and reactivates p53 to inhibit malignant transformation. Journal of Biological Chemistry 2014 Nov 7;289(45):31296-309

 

9. Mitra, Rajendra; Doshi, Mona; Zhang, Xiaolei; Tyus, Jessica; Bengtsson, Niclas; Fletcher, Steven; Page, Brent; Turkson, James; Gesquiere, Andre; Gunning, Patrick; Walter, Glenn; Santra, Swadeshmukul. An activatable multimodal/multifunctional nanoprobe for direct imaging of intercellular drug delivery.  Biomaterials. 2012, 33(5):1500-8

 

10. Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem. 2009, 10(12):1959-64

 

11. Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S, Turkson J, Gunning PT. Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules. ChemMedChem. 2011 6(8):1459-70

 

12. Drewry JA, Fletcher S, Yue P, Marushchak D, Zhao W, Sharmeen S, Zhang X, Schimmer AD, Gradinaru C, Turkson J, Gunning PT. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb). 2010 ,;46(6):892-4

 

13. Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett. 2011, 21(18):5605-9

 

14. Vijay M. Shahani, Peibin Yue, Sina Haftchenary, Wei Zhao, Julie L. Lukkarila, Xiaolei Zhang, Daniel Ball, Christina Nona, Patrick T. Gunning, and James Turkson. Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies  ACS Med. Chem. Lett., 2011 ,2(1):79-84.

 

15.  Shahani VM, Yue P, Fletcher S, Sharmeen S, Sukhai MA, Luu DP, Zhang X, Sun H, Zhao W, Schimmer AD, Turkson J, Gunning PT. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem. 2011, 19(5):1823-38


学术交流

1. Xiaolei Zhang, Teresa C. Leone, Rick B. Vega, Bret H. Goodpaster, Daniel P. Kelly, Paul M. Coen Mitochondria function dynamics in aging mouse model of unloading followed by reloading  APS Conference Physiological Bioenergetics: From Bench to Bedside, 2015, Tampa, FL

 

2. Zhang, Xiaolei, Trevino, Michelle, Leone, Teresa C., Vega, Rick, Goodpaster, Bret H., Han, Xianlin, Coen, Paul M. Distinct Temporal Sequence of Cardiolipin Remodeling, Loss of Mitochondrial Function, and Muscle Atrophy during Hind Limb Unloading. Advances in Sketetal Muscle Biology in Health and Disuse, 2016, Gainesiville, FL

 

3. Xiaolei Zhang, Michelle A. Blaskovich, Kara D. Forinash, and Said M. Sebti. Withacnistin blocks binding of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumors in vivo. AACR 105th  Annual Meeting, 2014, San Diego, CA, USA

 

4. Xiaolei Zhang, Ying Sun, Roberta Pireddu, Hua Yang, Murali K. Urlam, Harshani R. Lawrence, Wayne C. Guida, Nicholas J. Lawrence, Said M. Sebti. Discovery of S3I-1757, a STAT3-STAT3 dimerization disruptor that inhibits STAT3 activity, tumor survival, migration and invasion. AACR 104th  Annual Meeting, 2013, Washington DC, USA

 

5. Xiaolei Zhang, Peibin Yue, Brent D.G. Page, Steven Fletcher, Wei Zhao, Patrick T. Gunning, James Turskon. A novel orally-bioavailable salicylic acid-based small molecular Stat3 inhibitor suppress growth of human breast tumor xenografts. AACR 102nd Annual meeting 2011, Orlando, USA


其他

欢迎有兴趣的同学报考本研究,也非常欢迎博士后、研究助理等优秀科研人员加入。如需更多信息,请联系xiaolei.zhang@hotmail.com, 微信 xiaoleizhang2012